Non-Alcoholic Steatohepatitis (NASH) Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By Delveinsight

 Breaking News
  • No posts were found

Non-Alcoholic Steatohepatitis (NASH) Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By Delveinsight

May 11
20:18 2021
Non-Alcoholic Steatohepatitis (NASH) Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By Delveinsight

DelveInsight Business Research LLP
DelveInsight’s “Non-Alcoholic Steatohepatitis (NASH) – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Non-Alcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the Non-Alcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Non-Alcoholic Steatohepatitis (NASH)- Market Insights, Epidemiology, and Market Forecast-2030

DelveInsight’sNon-Alcoholic Steatohepatitis (NASH) – Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the  Non-Alcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the  Non-Alcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  1. Of all the prevalent cases of NAFLD in the 7MM, approximately 19% of the population fulfilled the criteria for NASH. These cases are expected to increase throughout the study period [2018–2030].

  2. We estimate the highest prevalence of NASH in the United States, accounting for close to 50% of the total prevalent cases, followed by Japan.

  3. On the other hand, it is assessed that among the European countries, Germany accounted for the highest prevalent population, followed by Italy. Among all the 7MM countries, Spain had the lowest prevalent population.

Key benefits of the report:

1. Non-Alcoholic Steatohepatitis (NASH) market report covers a descriptive overview and comprehensive insight of the Non-Alcoholic Steatohepatitis (NASH) epidemiology and Non-Alcoholic Steatohepatitis (NASH) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Non-Alcoholic Steatohepatitis (NASH) market report provides insights on the current and emerging therapies.

3. Non-Alcoholic Steatohepatitis (NASH) market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Non-Alcoholic Steatohepatitis (NASH) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Non-Alcoholic Steatohepatitis (NASH) market.

Request for sample pages: https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market

Non-Alcoholic Steatohepatitis (NASH): Overview

Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by a buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis

The key players involved in Non-Alcoholic Steatohepatitis (NASH) market:

  1. Enyo Pharma

  2. Terns Pharmaceuticals

  3. Ascletis Pharma

  4. Oramed Pharmaceuticals

  5. Can-Fite BioPharma

  6. Inventiva Pharma

  7. Madrigal Pharmaceuticals

  8. MediciNova

  9. TaiwanJ Pharmaceuticals

The launch of the emerging therapies is expected to significantly impact the  Non-Alcoholic Steatohepatitis (NASH) treatment scenario in the upcoming years:-

Drug covered

  1. EYP001

  2. TERN-101

  3. ASC40

  4. ORMD-0801

  5. Namodenoson (CF102)

  6. Lanifibranor (IVA33)

  7. Resmetirom (MGL-3196)

  8. MN-001 (Tipelukast)

  9. JKB-122

Request a free sample report @https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Non-Alcoholic Steatohepatitis (NASH) Patient Share (%) Overview at a Glance

5. Non-Alcoholic Steatohepatitis (NASH) Market Overview at a Glance

6. Non-Alcoholic Steatohepatitis (NASH) Disease Background and Overview

7. Non-Alcoholic Steatohepatitis (NASH) Epidemiology and Patient Population

8. Country-Specific Patient Population of  Non-Alcoholic Steatohepatitis (NASH)

9. Non-Alcoholic Steatohepatitis (NASH) Current Treatment and Medical Practices

10. Unmet Needs

11. Non-Alcoholic Steatohepatitis (NASH) Emerging Therapies

12. Non-Alcoholic Steatohepatitis (NASH) Market Outlook

13. Country-Wise  Non-Alcoholic Steatohepatitis (NASH) Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Non-Alcoholic Steatohepatitis (NASH) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Non-Alcoholic Steatohepatitis (NASH)- Pipeline Insights, 2021

Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Non-Alcoholic Steatohepatitis (NASH) market. A detailed picture of the Non-Alcoholic Steatohepatitis (NASH) pipeline landscape is provided, which includes the disease overview and Non-Alcoholic Steatohepatitis (NASH) treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories